NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Forecast & News

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.07 by $1.77. The biopharmaceutical company had revenue of $59.49 million for the quarter, compared to analyst estimates of $58.33 million. Vanda Pharmaceuticals had a net margin of 55.49% and a return on equity of 38.90%. Vanda Pharmaceuticals's revenue was up 21.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.13 earnings per share. View Vanda Pharmaceuticals' Earnings History.

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Vanda Pharmaceuticals.

Vanda Pharmaceuticals will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 Wall Street analysts have issued twelve-month target prices for Vanda Pharmaceuticals' shares. Their forecasts range from $17.00 to $19.00. On average, they expect Vanda Pharmaceuticals' share price to reach $18.00 in the next year. This suggests a possible upside of 47.6% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vanda Pharmaceuticals.

News articles about VNDA stock have trended neutral recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vanda Pharmaceuticals earned a news sentiment score of 0.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Vanda Pharmaceuticals.

Vanda Pharmaceuticals saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 4,010,000 shares, a decline of 10.3% from the December 31st total of 4,470,000 shares. Based on an average trading volume of 556,300 shares, the short-interest ratio is currently 7.2 days. Currently, 7.8% of the company's stock are short sold. View Vanda Pharmaceuticals' Current Options Chain.

Some companies that are related to Vanda Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Array Biopharma (ARRY), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Crispr Therapeutics (CRSP) and ImmunoGen (IMGN).

Vanda Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (8.48%), Renaissance Technologies LLC (6.47%), State Street Corp (4.75%), Prudential Financial Inc. (2.37%), Acadian Asset Management LLC (1.85%) and Geode Capital Management LLC (1.43%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Institutional Ownership Trends for Vanda Pharmaceuticals.

VNDA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Goldman Sachs Group Inc., FMR LLC, Charles Schwab Investment Management Inc., Rafferty Asset Management LLC, 361 Capital LLC, Pictet Asset Management Ltd. and Palo Alto Investors LP. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Insider Buying and Selling for Vanda Pharmaceuticals.

VNDA stock was bought by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Renaissance Technologies LLC, Bank of Montreal Can, Acadian Asset Management LLC, Man Group plc and Panagora Asset Management Inc.. View Insider Buying and Selling for Vanda Pharmaceuticals.

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VNDA stock can currently be purchased for approximately $12.20.

Vanda Pharmaceuticals has a market capitalization of $650.48 million and generates $193.12 million in revenue each year. The biopharmaceutical company earns $25.20 million in net income (profit) each year or $0.48 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe.View Additional Information About Vanda Pharmaceuticals.

The official website for Vanda Pharmaceuticals is http://www.vandapharma.com/.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]